GB Sciences, Inc.
GBLX · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.10 | 0.06 | -0.01 |
| FCF Yield | -21.79% | 5.48% | -0.72% | -9.79% |
| EV / EBITDA | -54.48 | -26.01 | -18.97 | -11.69 |
| Quality | ||||
| ROIC | 1.71% | 4.04% | 6.63% | 10.41% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.26 | 12.67 | 0.08 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 459,740.84% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -388.91% | 658.41% | 91.29% | -22.91% |
| Safety | ||||
| Net Debt / EBITDA | -29.97 | -11.83 | -6.93 | -4.72 |
| Interest Coverage | -1.97 | -4.83 | -8.23 | -3.81 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |